Crescita Therapeutics (CTX) Q3 2025 earnings summary

Executive summary

• Q3-25 revenue was $5.39M, up 50% year-over-year, driven by strong Manufacturing segment performance and new client volumes, with net income of $753K versus a net loss of $1.04M in Q3-24.

• Gross profit increased to $2.86M, and adjusted EBITDA improved to $262K from $(681)K year-over-year.

• Major asset acquisition of Laboratoire Provence-Canada Inc. (LPC) completed for $775K, integrating revenue-producing assets and securing a five-year supply agreement.

• Termination of Pliaglis licensing agreement with Croma Pharma resulted in a €575K (CA$902K) payment and regained rights in several territories.

• Cash at quarter-end was $8.3M, with working capital of $10.86M.

Financial highlights

• Q3-25 revenue: $5.39M (Q3-24: $3.59M); gross profit: $2.86M (Q3-24: $1.97M); net income: $753K (Q3-24: $(1.04)M).

• Adjusted EBITDA: $262K (Q3-24: $(681)K); gross margin: 52.9% (Q3-24: 54.7%).

• Nine-month revenue: $15.16M (2024: $12.68M); net income: $619K (2024: $(2.59)M).

• Cash provided by operating activities for Q3-25: $1.17M (Q3-24: $424K).

• Operating expenses decreased to $3.02M in Q3-25 (Q3-24: $3.14M); operating loss narrowed to $(162)K from $(1.17)M.

Outlook and guidance

• Sufficient cash and credit facility to fund operations and growth initiatives.

• No renewal of NCIB after September 2025; focus remains on organic growth, acquisitions, and manufacturing partnerships.

• Integration of acquired assets and new supply agreement expected to bolster recurring revenue and plant utilization.

• Management continues to seek new partnerships for Pliaglis in regained territories.

• Future profitability depends on successful execution of growth strategy and ability to raise additional financing if needed.